Table 1.

Effect of ECM components on tumor drug delivery.

ECM component	Strategy	Drug	References
Collagen synthesis	Fasudil treatment (ROCK inhibitor)	Gemcitabine	Whatcott et al., 2017
Collagen	Systemic treatment with collagenase	Anti-tumor antibody	Eikenes et al., 2004
Collagen	Systemic treatment with collagenase	DOX	Wang et al., 2018
Collagen	Treatment with TGFβ-inhibitor	DOX	Liu J. et al., 2012
Collagen and HA synthesis	Treatment with losartan	5-FU, DOX	Diop-Frimpong et al., 2011; Chauhan et al., 2013
Hyaluronic acid	Systemic treatment with hyaluronidase	Gemcitabine	Provenzano et al., 2012; Jacobetz et al., 2013
Hyaluronic acid	Systemic treatment with hyaluronidase	Liposomal DOX	Eikenes et al., 2005
Hyaluronic acid	HAS inhibition with 4-MU	Liposomal DOX	Kohli et al., 2014
Hyaluronic acid	HAS inhibition with 4-MU	5-FU	Yoshida et al., 2018
Lysyl oxidases	Overexpression of LOX or LOXL2, LOX(L)-inhibition with βAPN	DOX	Schutze et al., 2015